Creatine ( DrugBank: Creatine )

---

11 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
1	球脊髄性筋萎縮症	1
2	筋萎縮性側索硬化症	6
5	進行性核上性麻痺	1
6	パーキンソン病	2
8	ハンチントン病	6
46	悪性関節リウマチ	1
49	全身性エリテマトーデス	1
50	皮膚筋炎／多発性筋炎	2
113	筋ジストロフィー	3
156	レット症候群	1
201	アンジェルマン症候群	1

1. 球脊髄性筋萎縮症

---

臨床試験数 : 18 /  薬物数 : 15 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 17

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000012503	2014/06/01	25/12/2013	Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical study	Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical study - Creatine in SBMA	Spinal and Bulbar Muscular Atrophy	Creatine monohydrate 10 g, daily for 8 weeks Creatine monohydrate 15 g, daily for 8 weeks placebo for 8 weeks	Department of Neurology, Nagoya University Graduate School of Medicine	NULL	Complete: follow-up continuing	20years-old	80years-old	Male	45	Not applicable	Japan

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01257581 (ClinicalTrials.gov)	March 2011	8/12/2010	Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: creatine;Drug: tamoxifen	Nazem Atassi	ALS Therapy Alliance;State University of New York - Upstate Medical University	Completed	18 Years	N/A	All	60	Phase 2	United States
2	NCT00355576 (ClinicalTrials.gov)	July 2006	21/7/2006	Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis	Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Celecoxib;Drug: Creatine;Drug: Minocycline	Columbia University	ALS Association;Pfizer	Completed	21 Years	85 Years	Both	86	Phase 2	United States
3	NCT00069186 (ClinicalTrials.gov)	June 2003	17/9/2003	Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis (ALS)	Drug: Creatine Monohydrate	The Avicena Group	NULL	Active, not recruiting	21 Years	80 Years	Both	107	Phase 3	United States
4	NCT00070993 (ClinicalTrials.gov)	December 2002	9/10/2003	Creatine for the Treatment of Amyotrophic Lateral Sclerosis	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: creatine monohydrate	National Center for Complementary and Integrative Health (NCCIH)	Office of Dietary Supplements (ODS)	Completed	21 Years	80 Years	Both	110	Phase 2	United States
5	NCT00005766 (ClinicalTrials.gov)	May 2000	1/6/2000	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis		Amyotrophic Lateral Sclerosis	Drug: Creatinine	National Center for Research Resources (NCRR)	NULL	Completed	18 Years	80 Years	Both		Phase 2	United States
6	NCT00005674 (ClinicalTrials.gov)	May 2000	26/5/2000	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]		Amyotrophic Lateral Sclerosis	Drug: Creatine	National Center for Research Resources (NCRR)	Muscular Dystrophy Association	Completed	18 Years	80 Years	Both		Phase 2	United States

先頭へ

5. 進行性核上性麻痺

---

臨床試験数 : 89 /  薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00605930 (ClinicalTrials.gov)	April 2004	14/1/2008	A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.	Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.	Progressive Supranuclear Palsy	Dietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: Placebo	University of Louisville	NULL	Completed	N/A	N/A	All	20	N/A	United States

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00449865 (ClinicalTrials.gov)	March 2007	20/3/2007	NET-PD LS-1 Creatine in Parkinson's Disease	A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)	Parkinson's Disease	Drug: creatine;Other: placebo	University of Rochester	National Institute of Neurological Disorders and Stroke (NINDS)	Terminated	N/A	N/A	All	1741	Phase 3	United States;Canada
2	NCT00063193 (ClinicalTrials.gov)	May 2003	23/6/2003	National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial	A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease	Parkinson's Disease	Drug: minocycline;Drug: creatine	University of Rochester	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	30 Years	N/A	Both	195	Phase 2	United States

8. ハンチントン病

---

臨床試験数 : 242 /  薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01411163 (ClinicalTrials.gov)	April 2010	4/8/2011	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Huntington's Disease	Drug: Creatine monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	24	Phase 2	United States
2	NCT00712426 (ClinicalTrials.gov)	September 2009	8/7/2008	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Huntington's Disease	Drug: Creatine Monohydrate;Drug: Placebo	Massachusetts General Hospital	University of Rochester;National Center for Complementary and Integrative Health (NCCIH)	Terminated	18 Years	N/A	Both	553	Phase 3	United States;Australia;Canada;New Zealand
3	NCT01411150 (ClinicalTrials.gov)	May 2009	4/8/2011	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Huntington's Disease	Drug: Creatine Monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	38	Phase 2	United States
4	NCT00592995 (ClinicalTrials.gov)	December 2007	28/12/2007	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Huntington Disease	Drug: Creatine monohydrate;Drug: Placebo	Massachusetts General Hospital	NULL	Completed	26 Years	N/A	Both	64	Phase 2	United States
5	NCT01412151 (ClinicalTrials.gov)	April 2005	5/8/2011	Creatine Safety & Tolerability in Huntington's Disease	Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD	Huntington's Disease (HD)	Drug: Creatine monohydrate	Massachusetts General Hospital	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States
6	NCT00026988 (ClinicalTrials.gov)	October 2001	15/11/2001	Creatine Therapy for Huntington's Disease	Creatine Therapy for Huntington's Disease	Huntington's Disease	Drug: Creatine	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	18 Years	N/A	Both	64	Phase 1/Phase 2	United States

先頭へ

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01767844 (ClinicalTrials.gov)	January 2013	8/1/2013	Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients?	Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients? A Randomised Controlled Pilot Trial	Rheumatoid Arthritis	Dietary Supplement: Creatine;Dietary Supplement: Placebo	Bangor University	NULL	Active, not recruiting	18 Years	N/A	Both	43	N/A	United Kingdom

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01217320 (ClinicalTrials.gov)	January 2011	6/10/2010	Creatine Supplementation in Pediatric Rheumatology	Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis	Juvenile Systemic Lupus Erythematosus;Juvenile Dermatomyositis	Dietary Supplement: creatine;Dietary Supplement: placebo (dextrose)	University of Sao Paulo	NULL	Recruiting	6 Years	18 Years	Both	40	N/A	Brazil

50. 皮膚筋炎／多発性筋炎

---

臨床試験数 : 194 /  薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02267005 (ClinicalTrials.gov)	March 2015	1/10/2014	The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis	The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis	Juvenile Dermatomyositis	Dietary Supplement: Creapure;Dietary Supplement: Glucose Tablet	The Hospital for Sick Children	NULL	Completed	7 Years	18 Years	All	13	N/A	Canada
2	NCT01217320 (ClinicalTrials.gov)	January 2011	6/10/2010	Creatine Supplementation in Pediatric Rheumatology	Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis	Juvenile Systemic Lupus Erythematosus;Juvenile Dermatomyositis	Dietary Supplement: creatine;Dietary Supplement: placebo (dextrose)	University of Sao Paulo	NULL	Recruiting	6 Years	18 Years	Both	40	N/A	Brazil

113. 筋ジストロフィー

---

臨床試験数 : 646 /  薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-006776-37-NL (EUCTR)	14/05/2007	22/12/2006	Towards the assessment of metabolic biomarkers and creatine uptake and turnover in skeletal muscles of patients with Facioscapulohumeral muscular dystrophy using MR spectroscopy - Assessment of biomarkers in FSHD	Towards the assessment of metabolic biomarkers and creatine uptake and turnover in skeletal muscles of patients with Facioscapulohumeral muscular dystrophy using MR spectroscopy - Assessment of biomarkers in FSHD	Healthy volunteers. Later the protocol will be applied to Facioscapular humeral dystrophy and/or other muscular dystrophies in general. MedDRA version: 8.1;Level: LLT;Classification code 10011328;Term: Creatine	Product Name: creatine-13C Product Code: Cr13C	Radboud University Nijmegen Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
2	NCT00018109 (ClinicalTrials.gov)	June 2001	3/7/2001	A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)	A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)	Muscular Dystrophy, Duchenne	Drug: glutamine;Drug: creatine monohydrate	National Center for Research Resources (NCRR)	Children's Research Institute	Completed	5 Years	10 Years	Male		Phase 3	United States
3	NCT00016653 (ClinicalTrials.gov)	June 2000	21/5/2001	Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy	A Multicenter Randomized Placebo-controlled Double-blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy	Muscular Dystrophy, Duchenne	Drug: Creatine Monohydrate;Drug: Glutamine	Cooperative International Neuromuscular Research Group	NULL	Completed	5 Years	9 Years	Male	48	Phase 2/Phase 3	United States;Belgium;Israel;Puerto Rico

156. レット症候群

---

臨床試験数 : 44 /  薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01147575 (ClinicalTrials.gov)	January 2005	17/6/2010	Effects of Creatine Supplementation in Rett Syndrome	Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-controlled Trial	Rett Syndrome	Dietary Supplement: Creatine monohydrate;Dietary Supplement: Placebo	Medical University of Vienna	NULL	Completed	3 Years	24 Years	Female	21	N/A	Austria

201. アンジェルマン症候群

---

臨床試験数 : 25 /  薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00348933 (ClinicalTrials.gov)	July 2006	3/7/2006	Dietary Supplements for the Treatment of Angelman Syndrome	Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome	Angelman Syndrome;Nervous System Diseases	Drug: Betaine;Drug: Creatine;Drug: Metafolin;Drug: Vitamin B12	University of California, San Diego	Baylor College of Medicine;Rady Children's Hospital, San Diego;Boston Children’s Hospital;Greenwood Genetic Center;Rare Diseases Clinical Research Network	Completed	N/A	5 Years	All	90	N/A	United States

先頭へ